Nivolumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Classic Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin National Cancer Institute (NCI) | Phase 3 | BB |
VINBLASTINE University of Washington | Phase 3 | BB |
imm01 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 3 | B |
Cediranib Barbara Ann Karmanos Cancer Institute | Phase 3 | B |
Vinorelbine Michael Spinner, MD | Phase 3 | B |
View all 20 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →